Allergan’s Ophthalmic Therapy Meets Goals in Phase III Presbyopia Trial
by According to the data, AGN-190584 provided sustained vision gains for up to six hours with a 15-minute onset of action. In a Phase III GEMINI …
Article Mania – Bloggers Unite India
Your Place to post Quality Articles.
According to the data, AGN-190584 provided sustained vision gains for up to six hours with a 15-minute onset of action. In a Phase III GEMINI …